Mark your calendars for Monday 4th November 2024, as BioCryst Pharmaceuticals (NASDAQ: BCRX) will be revealing its third quarter financial results. This highly awaited announcement is scheduled to take place before market open, pave the way to review a period of expectation and anticipation.
According to the predictions of financial experts on Wall Street, the firm is set to unveil an estimated $0.06 loss per share for the quarter. Additionally, the company is expected to report a total revenue of $112.5 million for the specific period.
Wall Street analysts have unveiled their forecasts for the company's yearly performance, estimating a total revenue of $435.79 million. Additionally, they expect the company to reach loss of $0.36 per share for the fiscal year.
In comparison to the same quarter of the prior year, the company's financial statement showcased a per share of loss of $0.19. This was credited to the company's total revenue, which reached an impressive $86.74 million in that particular timeframe.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.06 | +75.0% | 109.33 M | +32.5% |
| Q1 2024 | $-0.17 | +39.3% | 92.76 M | +34.9% |
| Q4 2023 | $-0.28 | +26.3% | 93.40 M | +17.4% |
| Q3 2023 | $-0.19 | +17.4% | 86.74 M | +14.4% |
| Q2 2023 | $-0.24 | +25.0% | 82.49 M | +25.9% |
| *Growth on year-over-year basis | ||||
BCRX will host a conference call with investment community on 4th November 2024 at 08:30 AM eastern time to discuss the financial results.
BioCryst Pharmaceuticals (BCRX) shares traded as low as $8.00 and as high as $8.44 on a day volume of 2.82 million shares, closed Friday's regular trading session at $8.43, an increase of 5.24 percent.
